Empagliflozin, a treatment for type 2 diabetes that's being developed by Eli Lilly (LLY -1.3%)...

|About: Eli Lilly and Company (LLY)|By:, SA News Editor

Empagliflozin, a treatment for type 2 diabetes that's being developed by Eli Lilly (LLY -1.3%) and Boehringer Ingelheim, improved blood glucose levels and met the the primary goals of four Phase III studies. In total, the program comprises eight multinational trials. Eli Lilly and Boehringer intend to file for regulatory review in the U.S., Europe and Japan in 2013. (PR)